logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Handbook Of Anticancer Pharmacokinetics And Pharmacodynamics Cancer Drug Discovery And Development Cancer Drug Discovery And Development William D Figg

  • SKU: BELL-2534524
Handbook Of Anticancer Pharmacokinetics And Pharmacodynamics Cancer Drug Discovery And Development Cancer Drug Discovery And Development William D Figg
$ 31.00 $ 45.00 (-31%)

4.0

66 reviews

Handbook Of Anticancer Pharmacokinetics And Pharmacodynamics Cancer Drug Discovery And Development Cancer Drug Discovery And Development William D Figg instant download after payment.

Publisher: Humana Press
File Extension: PDF
File size: 10.17 MB
Pages: 643
Author: William D. Figg, Howard L. McLeod
ISBN: 1588291774
Language: English
Year: 2004
Edition: Cancer Drug Discovery and Development

Product desciption

Handbook Of Anticancer Pharmacokinetics And Pharmacodynamics Cancer Drug Discovery And Development Cancer Drug Discovery And Development William D Figg by William D. Figg, Howard L. Mcleod 1588291774 instant download after payment.

Leading investigators synthesize the entire laboratory and clinical process of developing anticancer drugs to create a single indispensable reference that covers all the steps from the identification of cancer-specific targets to phase III clinical trials. These expert authors provide their best guidance on a wide variety of issues, including clinical trial design, preclinical screening, and the development and validation of bioanalytic methods. The chapters on identifying agents to test in phase III trials and on trial design for the approval of new anticancer agents offer a unique roadmap for moving an agent to NDA submission.

Related Products